The change of neutrophils/lymphocytes ratio in migraine attacks: A case-controlled study

Karabulut, Keziban Uçar; Egercioglu, Tomris Ugur; Uyar, Mehmet; Uçar, Yıldız

doi:10.1016/j.amsu.2016.07.023

Cited by 37 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Episodic and chronic migraine various inflammatory biomarkers and migraines have been investigated by several researchers [3,19,20]. Many researchers have investigated the relationships between the features of headaches and inflammation using hematologic parameters [3,6,10,13,[21][22][23]. The main goal of these studies is to evaluate the inflammatory processes using hematological markers and to investigate the association of these markers with clinical parameters of headaches, and their utility in discriminating headache syndromes from other diseases [10,24].…”

Section: The Results Of the Comparisons Of Nlr Between The Patient Grmentioning

confidence: 99%

“…Many researchers have investigated the relationships between the features of headaches and inflammation using hematologic parameters [3,6,10,13,[21][22][23]. The main goal of these studies is to evaluate the inflammatory processes using hematological markers and to investigate the association of these markers with clinical parameters of headaches, and their utility in discriminating headache syndromes from other diseases [10,24]. A critical study by Ceylan et al investigating inflammatory markers in serum in migraine patients found higher levels of fibrinogen and pentraxin-3 (PTX-3) in migraine patients suffering acute attacks as compared to those in healthy control patients.…”

Section: The Results Of the Comparisons Of Nlr Between The Patient Grmentioning

confidence: 99%

“…NLR is an easily measured, reproducible, and inexpensive marker, and it is a parameter to be used also for subclinical inflammation [25]. Therefore, its utility on the clinical grounds including its diagnostic significance, prognostic role, and its possible contribution regarding the underlying pathophysiology has constituted an attractive topic of research interest [7,8,10]. The prognostic or diagnostic role of NLR has been investigated rather in a limited number of studies focusing on neurological disorders, which included patients with acute stroke, subarachnoid hemorrhage, restless leg syndrome, multiple sclerosis, and headaches [6-8, 10, 13, 26, 27].…”

Section: The Results Of the Comparisons Of Nlr Between The Patient Grmentioning

confidence: 99%

“…The prognostic or diagnostic role of NLR has been investigated rather in a limited number of studies focusing on neurological disorders, which included patients with acute stroke, subarachnoid hemorrhage, restless leg syndrome, multiple sclerosis, and headaches [6-8, 10, 13, 26, 27]. To the best of our knowledge, there are only three previous reports evaluating the significance of the NLR for the evaluation of patients with migraine [8,10,13]. In the study by Karabulut et al on 92 patients with migraines during the attack period, the value of NLR was found to be higher in the patients, compared to the controls [10].…”

Section: The Results Of the Comparisons Of Nlr Between The Patient Grmentioning

confidence: 99%

“…However, even when WBC is within normal limits, an increased neutrophil to lymphocyte ratio (NLR) may indicate inflammation and inflammation-related pathologies [4]. The NLR has been used in the evaluation and prognostication of various diseases, including coronary artery diseases, malignancies, rheumatologic diseases, and neurological diseases [5][6][7][8][9][10][11][12]. Few studies have investigated the value of this marker in the evaluation of migraineurs [8,10,13].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

May Neutrophil to Lymphocyte Ratio Serve a Role in the Prediction of Clinical Features of Migraine?

Önder

Deliktas

2020

J Neurol Res

View full text Add to dashboard Cite

Background: We aimed to investigate the possible association between the value of neutrophil to lymphocyte ratio (NLR) and some specific features of migraine. Methods:We have included initially all the patients with migraine who applied to our neurology clinic in Yozgat City Hospital during December 2019 and agreed to participate in this study. The demographic and clinical characteristics including migraine subtype (episodic/chronic), headache frequency per month, headache characteristics of all patients were interrogated. Besides, the presence of fibromyalgia (FM) and chronic fatigue syndrome (CFS) was also noted. The severity of migraine was assessed using the headache impact test (HIT-6) and the severity of chronic fatigue was assessed using the Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale. A hemogram was performed upon admission to the clinic. The patients with migraine attacks during the clinic visits were excluded from the study.Results: Ultimately, 52 migraineurs were included in this study. The mean age was 37.34 ± 11.80 and the female/male (F/M) ratio was 49/3. Thirty-six patients (69%) were diagnosed with episodic migraine (EM), and 16 of them (31%) were diagnosed with chronic migraine (CM). The results of the comparative analyses between EM and CM groups showed that the NLR did not differ between groups. To evaluate the possible association of the NLR with other clinical parameters, additional comparative analyses evaluating the presence of FM, CFS, cognitive symptoms and tinnitus were also conducted, which showed no significant differences. The results of the correlation analyses to evaluate the possible associations between the NLR value and other clinical parameters were also unremarkable. Conclusions:We suggest that the NLR cannot be a specific marker to be used in the differential diagnosis or prediction of any features of migraines during the interictal period. However, in light of the previous reports, the utility of this value in the differentiating of migraine attacks from other causes of headache attacks can be investigated in future related studies.

show abstract

Section: The Results Of the Comparisons Of Nlr Between The Patient Grmentioning

confidence: 99%

Section: The Results Of the Comparisons Of Nlr Between The Patient Grmentioning

confidence: 99%

Section: The Results Of the Comparisons Of Nlr Between The Patient Grmentioning

confidence: 99%

Section: The Results Of the Comparisons Of Nlr Between The Patient Grmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

May Neutrophil to Lymphocyte Ratio Serve a Role in the Prediction of Clinical Features of Migraine?

Önder

Deliktas

2020

J Neurol Res

View full text Add to dashboard Cite

show abstract

Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression

et al. 2019

View full text Add to dashboard Cite

IMPORTANCE To our knowledge, no study has previously evaluated whether individuals with bipolar depression enriched a priori on the basis of biochemical and/or phenotypic immuno-inflammatory activation would differentially respond to an anti-inflammatory agent for the treatment of depressive symptoms. OBJECTIVE To assess the antidepressant efficacy of adjunctive infliximab, a monoclonal antibody targeting tumor necrosis factor, in adults with bipolar I and bipolar II depression and inflammatory conditions. DESIGN, SETTING, AND PARTICIPANTS This 12-week, randomized, double-blind, placebo-controlled, parallel-group trial of 60 participants was conducted at 2 outpatient tertiary care sites in Canada and the United States. Eligible adults (aged 18-65 years) met DSM-5-defined criteria for bipolar I or bipolar II depression and exhibited pretreatment biochemical and/or phenotypic evidence of inflammatory activation. Participants were enrolled between October 1, 2015, and April 30, 2018. Data analysis was performed from May 1 through July 31, 2018, using modified intent-to-treat analysis. INTERVENTIONS Patients were randomized to receive 3 intravenous infusions of infliximab therapy or placebo at baseline and at weeks 2 and 6 of the 12-week study. MAIN OUTCOMES AND MEASURES The primary efficacy outcome was baseline-to-end point (ie, week-12) change in Montgomery-Asberg Depression Rating Scale (MADRS) total score. History of childhood maltreatment, as assessed by the Childhood Trauma Questionnaire, was used for exploratory analyses as 1 of several secondary outcomes. RESULTS A total of 60 participants were randomized to infliximab (n = 29 [48%]; mean [SD] age, 45.0 [11.7] years; 20 of 28 female [71%]) or to placebo (n = 31 [52%]; mean [SD] age, 46.8 [10.2] years; 26 of 30 female [87%]) across study sites. Overall baseline-to-end point change in MADRS total score was observed across treatment × time interaction (χ 2 = 10.33; P = .04); reduction in symptom severity was not significant at week 12 (relative risk, 1.09; 95% CI, 0.80-1.50; df= 1; P = .60). As part of a secondary analysis, a significant treatment × time × childhood maltreatment interaction was observed in which infliximab-treated individuals with childhood history of physical abuse exhibited greater reductions in MADRS total score (χ 2 = 12.20; P = .02) and higher response rates (Ն50% reduction in MADRS total score) (χ 2 = 4.05; P = .04). CONCLUSIONS AND RELEVANCE Infliximab did not significantly reduce depressive symptoms compared with placebo in adults with bipolar depression. Results from secondary analyses identified a subpopulation (ie, those reporting physical and/or sexual abuse) that exhibited a significant reduction in depressive symptoms with infliximab treatment compared with placebo.

show abstract

Mechanisms

Martelletti

2022

Migraine in Medicine

View full text Add to dashboard Cite

The change of neutrophils/lymphocytes ratio in migraine attacks: A case-controlled study

Cited by 37 publications

References 23 publications

May Neutrophil to Lymphocyte Ratio Serve a Role in the Prediction of Clinical Features of Migraine?

May Neutrophil to Lymphocyte Ratio Serve a Role in the Prediction of Clinical Features of Migraine?

Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression

Mechanisms

Contact Info

Product

Resources

About